196 related articles for article (PubMed ID: 10727512)
1. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.
Rousselle C; Clair P; Lefauconnier JM; Kaczorek M; Scherrmann JM; Temsamani J
Mol Pharmacol; 2000 Apr; 57(4):679-86. PubMed ID: 10727512
[TBL] [Abstract][Full Text] [Related]
2. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity.
Rousselle C; Smirnova M; Clair P; Lefauconnier JM; Chavanieu A; Calas B; Scherrmann JM; Temsamani J
J Pharmacol Exp Ther; 2001 Jan; 296(1):124-31. PubMed ID: 11123372
[TBL] [Abstract][Full Text] [Related]
3. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
4. Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy.
Rousselle C; Clair P; Temsamani J; Scherrmann JM
J Drug Target; 2002 Jun; 10(4):309-15. PubMed ID: 12164379
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
[TBL] [Abstract][Full Text] [Related]
6. Effects of gamma- and hydroxypropyl-gamma-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier.
Monnaert V; Betbeder D; Fenart L; Bricout H; Lenfant AM; Landry C; Cecchelli R; Monflier E; Tilloy S
J Pharmacol Exp Ther; 2004 Dec; 311(3):1115-20. PubMed ID: 15280439
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-peptide conjugates overcome multidrug resistance.
Mazel M; Clair P; Rousselle C; Vidal P; Scherrmann JM; Mathieu D; Temsamani J
Anticancer Drugs; 2001 Feb; 12(2):107-16. PubMed ID: 11261883
[TBL] [Abstract][Full Text] [Related]
8. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
9. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
11. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration.
Xu X; Li J; Han S; Tao C; Fang L; Sun Y; Zhu J; Liang Z; Li F
Eur J Pharm Sci; 2016 Jun; 88():178-90. PubMed ID: 26965003
[TBL] [Abstract][Full Text] [Related]
12. Quaternary ammonium beta-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier.
Gil ES; Li J; Xiao H; Lowe TL
Biomacromolecules; 2009 Mar; 10(3):505-16. PubMed ID: 19216528
[TBL] [Abstract][Full Text] [Related]
13. Localized delivery of therapeutic doxorubicin dose across the canine blood-brain barrier with hyperthermia and temperature sensitive liposomes.
Bredlau AL; Motamarry A; Chen C; McCrackin MA; Helke K; Armeson KE; Bynum K; Broome AM; Haemmerich D
Drug Deliv; 2018 Nov; 25(1):973-984. PubMed ID: 29688083
[TBL] [Abstract][Full Text] [Related]
14. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
[TBL] [Abstract][Full Text] [Related]
15. Nanomicelles based on X-shaped four-armed peglyated distearylglycerol as long circulating system for doxorubicin delivery.
Zhang W; Sun J; Fang W; Ai X; Cai C; Tang Y; Su X; Feng Z; Liu Y; Tao M; Yan X; Chen G; He Z
Eur J Pharm Sci; 2015 Jan; 66():96-106. PubMed ID: 25446512
[TBL] [Abstract][Full Text] [Related]
16. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
Birngruber T; Raml R; Gladdines W; Gatschelhofer C; Gander E; Ghosh A; Kroath T; Gaillard PJ; Pieber TR; Sinner F
J Pharm Sci; 2014 Jul; 103(7):1945-1948. PubMed ID: 24801480
[TBL] [Abstract][Full Text] [Related]
17. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.
Lin Q; Mao KL; Tian FR; Yang JJ; Chen PP; Xu J; Fan ZL; Zhao YP; Li WF; Zheng L; Zhao YZ; Lu CT
Cancer Chemother Pharmacol; 2016 Feb; 77(2):269-80. PubMed ID: 26666650
[TBL] [Abstract][Full Text] [Related]
18. Modeling localized delivery of Doxorubicin to the brain following focused ultrasound enhanced blood-brain barrier permeability.
Nhan T; Burgess A; Lilge L; Hynynen K
Phys Med Biol; 2014 Oct; 59(20):5987-6004. PubMed ID: 25230100
[TBL] [Abstract][Full Text] [Related]
19. Short Peptide-Mediated Brain-Targeted Drug Delivery with Enhanced Immunocompatibility.
Guan J; Jiang Z; Wang M; Liu Y; Liu J; Yang Y; Ding T; Lu W; Gao C; Qian J; Zhan C
Mol Pharm; 2019 Feb; 16(2):907-913. PubMed ID: 30666875
[TBL] [Abstract][Full Text] [Related]
20. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
Saito Y; Buciak J; Yang J; Pardridge WM
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10227-31. PubMed ID: 7479757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
